72
Views
1
CrossRef citations to date
0
Altmetric
Review

Management of Adult Patients with Long-Standing Complex Regional Pain Syndrome

Pages 137-146 | Published online: 28 Feb 2013
 

Abstract

SUMMARY Approximately 15% of patients with complex regional pain syndrome will experience no improvement in their condition within the first 12 months. This group should be considered as having a long-term condition. Recently published clinical studies and national guidelines can support clinicians to devise rational approaches to the management of this group; however, conclusive evidence is still lacking for almost all aspects of care. A multidisciplinary approach to managing long-standing complex regional pain syndrome appears best suited to ensure high-quality care. This should allow effective functional rehabilitation. Unfortunately, however, meaningful pain relief is often not achieved with currently available treatment methods. Recently published novel treatment approaches will probably provide more patients with long-term pain relief in the future, but confirmatory trials are required.

Acknowledgments

Members of the UKCRPS network, the Liverpool CRPS pathway and the UKCRPS guidelines group have made important contributions to work that underlies this review.

Financial & competing interests disclosure

A Goebel has received research support from CSL-Behring, BPL, Biotest, Talecris, Baxter, Grifols and Pfizer; travel support from CSL-Behring and Baxter; speaker honoraria from Baxter; and consultancy fees from Biotest and Axsone. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Additional information

Funding

A Goebel has received research support from CSL-Behring, BPL, Biotest, Talecris, Baxter, Grifols and Pfizer; travel support from CSL-Behring and Baxter; speaker honoraria from Baxter; and consultancy fees from Biotest and Axsone. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.